IMR Press / EJGO / Volume 23 / Issue 2 / pii/2002122

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum - a systematic review of the evidence from randomized trials

Show Less
1 Department of Obstetrics and Gynaecology, University of Ottawa, Ottowa, ON Head, Division of Surgical Oncology, Ottawa Regional Cancer Centre, Ottawa ON Chair, Gynecology Disease Site Group, Cancer Care Ontario Practice Guidelines Initiative, Ottowa ON (Canada)
2 Research Assistant, Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton ON (Canada)
3 Director; Investigational New Drug Program, National Cancer Institute of Canada Clinical Trials Group; Professor, Department of Oncology, Queens University; Kingston ON (Canada)
4 Gynecologic Oncologist, Division of Gynecologic Oncology, Hamilton Regional Cancer Centre; Assistant Professor; Department of Obstetrics & Gynecology, McMaster University; Hamilton ON (Canada)
5 Head of Medical Oncology, Hamilton Regional Cancer Centre; Associate Professor, Departments of Medicine and Obstetrics & Gynecology, McMaster University; Hamilton ON (Canada)
6 Associate Professor, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Toronto, Toronto ON (Canada)

On behalf of the Cancer Care Ontario Practice Guidelines Initiative Gynecology Disease Site Group

Eur. J. Gynaecol. Oncol. 2002, 23(2), 104–110;
Published: 10 April 2002

Purpose: To evaluate the chemotherapeutic options for women with recurrent epithelial ovarian cancer who have received plati­num-based chemotherapy. Methods: A systematic search of the Medline, CancerLit and Cochrane Library databases was performed for the period from 1984 to June 2001 to find randomized trials comparing second- or higher-line chemotherapy regimens in patients with recurrent plati­num-pretreated epithelial ovarian cancer. Results: Seven randomized trials have failed to demonstrate the clear superiority of any one chemotherapy regimen in terms of improvements in long-term survival, quality of life or response rate. One trial detected a statistically significant difference between treatments in progression-free survival, which was longer with cyclophosphamide/doxorubicin/cisplatin than with paclitaxel in women with platinum-sensitive ovarian cancer. Another trial did not show a difference between liposomal doxorubicin and topote­can overall in women with recurrent ovarian cancer but a subgroup analysis detected a significant survival advantage for liposomal doxorubicin over topotecan in women with platinum-sensitive disease. Conclusion: The evidence available does not support firm conclusions about the preferred chemotherapy regimen for recurrent ovarian cancer. Randomized trials that compare new drugs with current standard treatments are needed.

Ovarian cancer
Back to top